IMR Press / EJGO / Volume 34 / Issue 4 / pii/1630906360321-740577360

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Epidemiology of HPV-related female cancers in the Umbria region of Italy: pre-vaccination period
Show Less
1 Department of Medical-Surgical Specialties & Public Health, Public Health Section, University of Perugia, Perugia
2 Post-graduate School of Public Health and Preventive Medicine, University of Perugia, Perugia
3 Umbrian Population Cancer Registry, Umbria Regional Health Office, Perugia
4 Department of Electronic and Information Engineering, University of Perugia, Perugia (Italy)
Eur. J. Gynaecol. Oncol. 2013, 34(4), 311–318;
Published: 10 August 2013

The authors describe the incidence and mortality rates of human papillomavirus (HPV)-related female cancers in Umbria (Italy) in the pre-vaccination period from 1978-2008. Joinpoint regression was applied on age-adjusted incidence and mortality rates to evaluate temporal trends. Mouth and pharynx cancers incidence and mortality trends decreased about three percent per year. For anus and anal canal cancer, incidence and mortality trends presented a non-significant decrease. For malignant neoplasm of vulva, a significant change was found in incidence trend: the annual percentage change decreased from 2001 (- 1.8%). Mortality trend showed a non-significant decrease. Incidence and mortality rates from vaginal cancer were non-significantly decreased. For malignant neoplasm of cervix uteri, incidence rates showed a significant decrease by 2.1% per year. Mortality rates decreased as well, although non-significantly. HPV-related cancers consistently decreased in Umbria. This trend may be a consequence of safer sexual behavior. For cervical cancer, a combinationof opportunistic and programmed screening led to a much-reduced disease burden. It is expected that the implementation of vaccination in the future will lead to a further decrease of HPV-related cancer incidence and mortality.
HPV-related cancers
Back to top